Business News • PR NewsWire • NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance

NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance

NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance

EAST HANOVER, N.J., March 14 /PRNewswire/ -- Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a c

View More : http://www.prnewswire.com/news-releases/navigator-shows-valsartan-delayed-progression-to-type-2-diabetes-in-at-risk-card...

Releted News by prnewswire

New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition

Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use

Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010

Asian Pacific American Municipal Officials Constituency Group Elects New Officers

Hydra Genome Sequenced by J. Craig Venter Institute and Multi-National Research Team